Lumida
/TSHA
⌘K
Taysha Gene Therapies Inc

Taysha Gene Therapies Inc

TSHA
$5.02USD-2.71%-0.14 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$3
$7

AI Summary

Stalk
TrimMedium

TSHA remains in medium-term distribution with active lower highs and lower lows under declining EMAs, trading near extreme oversold levels at the 200-day SMA. The medium-term bias is bearish, but short-term exhaustion and oversold RSI suggest caution on new shorts. Execution is best deferred into rallies toward the 9/20 EMA zone for rejection. The long-term uptrend stays intact above the rising 200-day SMA. Key risks include a relief bounce reclaiming the 20 EMA or a breakdown below the 200-day SMA invalidating core structural signals.

  • Breakthrough therapy designation and 100% early trial response rate accelerate BLA path.
  • Catalent manufacturing agreement ensures scalable supply for anticipated 2027 launch.
  • Net loss of $109M and $86.4M R&D spend in 2025 strain finances.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.5M$15.5M$8.3M$9.8M
YoY %+517.5%-46.1%+17.3%
P / Sales38.6x12.9x51.9x179.9x
EV / Sales53.6x9.9x45.9x157.1x
Gross Profit, Adj.$2.5M$15.5M$8.3M$9.8M
YoY %+517.5%-46.1%+17.3%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit53.6x9.9x45.9x157.1x
EBITDA, Adj.$-123.5M$-70.0M$-85.4M$-109.4M
YoY %+28.5%+43.3%-22.0%-28.1%
Margin %-4937.6%-453.1%-1024.6%-1118.9%
EV / EBITDA-1.1x-2.2x-4.5x-14.0x
EBIT$-162.4M$-72.4M$-91.5M$-110.5M
YoY %+6.2%+55.4%-26.3%-20.8%
Margin %-6492.7%-468.8%-1097.6%-1130.6%
EV / EBIT-0.8x-2.1x-4.2x-13.9x
Net Income$-166.0M$-111.6M$-89.3M$-109.0M
YoY %+4.9%+32.8%+20.0%-22.1%
Net Margin-6635.3%-722.1%-1071.6%-1115.3%
EPS (GAAP)-$3.78-$0.96-$0.36-$0.34
YoY %+18.5%+74.6%+62.5%+5.6%